Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 29, Number 7—July 2023
Extensively Drug-Resistant Shigella flexneri 2a, California, USA, 2022
Suggested citation for this article
In Los Angeles, California, USA, persistent, refractory shigellosis was diagnosed in an immunocompetent man who has sex with men. Whole-genome sequencing augmented phenotypic antimicrobial susceptibility testing to comprehensively profile bacterial drug resistance and appropriately guide therapy and clear the infection.
Shigellosis is an infectious diarrheal illness traditionally associated with contaminated food and water (1). Recent reports, however, have indicated increased transmission through sexual activity, including direct (anal/oral sex) and indirect (use of contaminated objects such as sex toys) sexual contact (2). Several outbreaks of extensively drug-resistant (XDR) Shigella spp. among men who have sex with men (MSM) have been described (3–5).
Recently, the emergence of sexually transmitted XDR Shigella flexneri serotype 2a was reported among gay, bisexual, and other MSM in England (4). The study by the UK Health Security Agency characterized S. flexneri isolates harboring blaCTX-M-27 and identified the 2 phylogenetically related clusters, each composed of isolates within 10 single-nucleotide polymorphisms (SNPs). Long-read sequencing elucidated the genomic location of the resistance determinant, and plasmid similarities with XDR Shigella sonnei from a current outbreak supported interspecies horizontal acquisition of drug resistance. Those findings underscore the substantial threat of mobilizable genetic elements and their role in propagating antimicrobial resistance (AMR). We describe a case of extensively drug-resistant S. flexneri infection in a 36-year-old man in California, USA.
The patient was an HIV-negative man who has sex with men and who had a history of shigellosis (S. flexneri type 1) 1.5 years earlier and mpox 4 months earlier. He sought hospital care for fever, abdominal pain, nonbloody watery diarrhea, and mild leukopenia. A fecal culture grew S. flexneri type 2, which was treated with ciprofloxacin for 4 days. Antimicrobial susceptibility testing (AST) was not requested. The patient’s sign/symptoms and leukocyte count slowly improved, although he continued to have loose bowel movements with mucous. He was referred for outpatient infectious diseases consultation. At that time, the patient’s history included frequent anonymous sexual encounters, typically including performing and receiving fellatio, analingus, and insertive anal intercourse; he stated he always wore condoms for intercourse but did not use barrier protection for fellatio or analingus. Testing for other sexually transmitted infections (including gonorrhea, chlamydia, HIV infection, and syphilis) produced negative results. Because his signs/symptoms were persistent, we sent repeat fecal samples to the UCLA Health Clinical Microbiology Laboratory for bacteria and parasites studies, including the BD Max Enteric Bacterial Panel PCR test (BD, https://www.bd.com), and results were again positive for Shigella spp. The patient elected to undergo observation only, and no additional treatment was provided.
Subsequent fecal samples sent several weeks later were again positive for S. flexneri, and the Los Angeles County Public Health Laboratory serotyped the cultured isolate as 2a. AST of the most recent isolate identified extensive AMR (Table). The patient was asymptomatic at that time. Because of a lack of other oral antimicrobial options, on the basis of AST results we chose minocycline for initial treatment to avoid parenteral treatment and the associated risks, solely to reduce bacterial shedding.
Ultimately, inconsistencies in AST results together with concerns over the XDR phenotype prompted whole-genome sequencing (WGS) of the isolate with the Illumina MiSeq platform (Illumina, https://www.illumina.com). K-mer–based phylogenic analysis (KmerFinder version 3.2, https://cge.food.dtu.dk/services/KmerFinder) identified S. flexneri 2a strain 981 as the most closely related reference, with 99.70% genome coverage and 98.20% pairwise identity (6–8). We performed further SNP analysis for microbial relatedness against a previously sequenced multidrug-resistant S. flexneri 2a isolate (UCLA 2020, which did not carry a CTX-M gene) from man who has sex with men residing in Riverside, California, along with the publicly available sequences from the United Kingdom study, which were all serotype 2a with plasmid-borne blaCTX-M-27 (4,9). Analysis revealed that the 2 California isolates are closely related to the UK S. flexneri strains, which contain <200 SNPs (Figure).
AMR gene analysis performed by using ResFinder version 4.0 (https://cge.food.dtu.dk/services/ResFinder) identified a compendium of AMR genes that not only corroborated the phenotypic AST results but also reconciled the ambiguous or discrepant categorical results within classes of antimicrobials (Table). Specifically, detection of blaCTX-M-15 indicated that an extended-spectrum β-lactamase enzyme had been acquired and suggested resistance to all cephalosporins, which contrasts with the elevated, yet susceptible, MIC for ceftazidime and cefepime. Detection of tet(B) indicated that resistance to tetracyclines is not limited to doxycycline but also includes minocycline, again in contrast with the elevated, yet susceptible, MIC determined by AST. Moreover, the absence of detectable fosfomycin resistance–conferring gene(s) provided confidence that fosfomycin was appropriate for patient management.
Thus, with information from the WGS-based genomic characterization, we replaced minocycline treatment with fosfomycin (3 g by mouth every other day for 3 doses). Three weeks after completing treatment with fosfomycin, the patient’s PCR result was negative, indicating clearance of Shigella.
In summary, persistent shigellosis caused by XDR S. flexneri was successfully treated with fosfomycin, as guided by WGS. Moreover, we demonstrate the genetic relatedness of 2 isolates from California to an ongoing outbreak in Europe, although with different CTX-M genes. This case illustrates the clinical value of WGS not only for providing a more comprehensive bacterial drug resistance profile but also for tracking the global epidemiology of clinically important organisms.
Dr. Caldera is a clinical microbiology fellow at the University of California, Los Angeles, California. His primary research interest focuses on the development of diagnostic assays that use advanced molecular and sequencing techniques in clinical microbiology.
We thank Naeemah Logan for her expertise and guidance.
- National Institutes of Health, National Institute of Allergy and Infectious Diseases. Shigellosis [cited 2023 Mar 23]. https://www.niaid.nih.gov/diseases-conditions/shigellosis
- Centers for Disease Control and Prevention. Shigella infection among gay, bisexual, and other men who have sex with men [cited 2023 Mar 24]. https://www.cdc.gov/shigella/msm.html
- Charles H, Prochazka M, Thorley K, Crewdson A, Greig DR, Jenkins C, et al.; Outbreak Control Team. Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021-22: a descriptive epidemiological study. Lancet Infect Dis. 2022;22:1503–10. DOIPubMedGoogle Scholar
- Thorley K, Charles H, Greig DR, Prochazka M, Mason LCE, Baker KS, et al. Emergence of extensively drug-resistant and multidrug-resistant Shigella flexneri serotype 2a associated with sexual transmission among gay, bisexual, and other men who have sex with men, in England: a descriptive epidemiological study. Lancet Infect Dis. 2023;S1473-3099(22)00807-6.
- Lefèvre S, Njamkepo E, Feldman S, Ruckly C, Carle I, Lejay-Collin M, et al. Rapid emergence of extensively drug-resistant Shigella sonnei in France. Nat Commun. 2023;14:462. DOIPubMedGoogle Scholar
- Hasman H, Saputra D, Sicheritz-Ponten T, Lund O, Svendsen CA, Frimodt-Møller N, et al. Rapid whole-genome sequencing for detection and characterization of microorganisms directly from clinical samples. J Clin Microbiol. 2014;52:139–46. DOIPubMedGoogle Scholar
- Larsen MV, Cosentino S, Lukjancenko O, Saputra D, Rasmussen S, Hasman H, et al. Benchmarking of methods for genomic taxonomy. J Clin Microbiol. 2014;52:1529–39. DOIPubMedGoogle Scholar
- Clausen PTLC, Aarestrup FM, Lund O. Rapid and precise alignment of raw reads against redundant databases with KMA. BMC Bioinformatics. 2018;19:307. DOIPubMedGoogle Scholar
- Kamau E, Adamson PC, Crandall J, Mukhopadhyay R, Yang S. Discovery of a novel sub-lineage of multi-drug resistant Shigella flexneri in Southern California. Int J Infect Dis. 2023;132:1–3. DOIPubMedGoogle Scholar
Suggested citation for this article: Caldera JR, Yang S, Uslan DZ. Extensively drug-resistant Shigella flexneri 2a, California, USA, 2022. Emerg Infect Dis. 2023 Jul [date cited]. https://doi.org/10.3201/eid2907.230465
Original Publication Date: May 19, 2023
Table of Contents – Volume 29, Number 7—July 2023
|EID Search Options|
|Advanced Article Search – Search articles by author and/or keyword.|
|Articles by Country Search – Search articles by the topic country.|
|Article Type Search – Search articles by article type and issue.|
Please use the form below to submit correspondence to the authors or contact them at the following address:
Daniel Z. Uslan, UCLA Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Ste 301, 911 Broxton Ave, Los Angeles, CA 90024, USA